A retrospective pooled analysis of duloxetine safety in 23 983 subjects

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Current Medical Research and Opinion

• Publication date

  2007-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1185/030079906X162719PMID 17257478
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Duloxetine

  2019cited by this paper
• Duloxetine: Meta-analyses of Suicidal Behaviors and Ideation in Clinical Trials for Major Depressive Disorder

  2006cited by this paper
• Duloxetine for the treatment of stress urinary incontinence in women: an integrated analysis of safety.

  2006cited by this paper
• Drug-related hepatotoxicity.

  2006cited by this paper
• Drug-related hepatotoxicity.

  2006cited by this paper
• A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder

  2005cited by this paper
• A double-blind, randomized multicenter trial comparing duloxetine with placebo in the management of diabetic peripheral neuropathic pain.

  2005cited by this paper
• Safety and tolerability of duloxetine in the treatment of major depressive disorder: analysis of pooled data from eight placebo‐controlled clinical trials

  2005cited by this paper
• Clinical consequences of initial duloxetine dosing strategies: Comparison of 30 and 60 mg QD starting doses.

  2005cited by this paper
• Dual serotonin and noradrenaline uptake inhibitor class of antidepressants potential for greater efficacy or just hype?

  2002cited by this paper
• Duloxetine Eli Lilly & Co.

  2000influential reference
• Adverse Reactions of Selective Serotonin Reuptake Inhibitors

  1999cited by this paper
• Spinal 5‐HT2 receptor‐mediated facilitation of pudendal nerve reflexes in the anaesthetized cat

  1996cited by this paper
• The projections of noradrenergic neurons in the A5 catecholamine cell group to the spinal cord in the rat: anatomical evidence that A5 neurons modulate nociception.

  1993cited by this paper
• Effect of 5-HT receptor and adrenoceptor antagonists on micturition in conscious cats.

  1992cited by this paper
• Alpha 2-adrenoceptors not imidazole receptors mediate depression of a sacral spinal reflex in the cat.

  1991cited by this paper
• Unmasking of a neonatal somatovesical reflex in adult cats by the serotonin autoreceptor agonist 5-methoxy-N,N-dimethyltryptamine.

  1990cited by this paper
• Evidence for a spinal site of action of clonidine on somatic and viscerosomatic reflex activity evoked on the pudendal nerve in cats.

  1988cited by this paper
• Experimental evidence for a central nervous system site of action in the effect of alpha-adrenergic blockers on the external urinary sphincter.

  1984cited by this paper
• Endogenous pain control systems: brainstem spinal pathways and endorphin circuitry.

  1984cited by this paper
• Effect of the alpha‐adrenergic blocking agent thymoxamine on the neurogenic bladder and urethra

  1980cited by this paper
• Effects of clonidine on the lumbar sympathetic pathways to the large intestine and urinary bladder of the cat.

  1979cited by this paper

• Monoamine-Uptake Inhibitors and Pain: Antidepressant Drugs Among First-Line Treatments Against Neuropathic Pain and Fibromyalgia.

  2025cites this paper
• Efficacy and safety of preoperative duloxetine in reducing post-laparoscopic surgery pain: a meta-analysis of randomized placebo-controlled trials

  2025cites this paper
• [Lymphocytic colitis associated with duloxetine].

  2024cites this paper
• Audio-Visual Stimulation Therapy for Chronic Neuropathic Pain: A Sham-Controlled Randomized Clinical Trial

  2024cites this paper
• Framework to leverage physical therapists for the assessment and treatment of chemotherapy-induced peripheral neurotoxicity (CIPN)

  2023cites this paper
• Duloxetine for Postoperative Pain Control Following Knee or Hip Replacement: A Systematic Review and Meta-Analysis

  2023cites this paper
• Psychological and Psychopharmacological Interventions in Psychocardiology

  2022cites this paper
• Expert review and recommendations for the management of acute, chronic, and neuropathic pain in Qatar.

  2021cites this paper
• Therapeutic Potential of Polyphenols in the Management of Diabetic Neuropathy

  2021cites this paper
• Metabolism of a Selective Serotonin and Norepinephrine Reuptake Inhibitor Duloxetine in Liver Microsomes and Mice

  2021cites this paper
• Histological assessment of liver and stomach damage caused by pyridazinone derivative antidepressant agents

  2021cites this paper
• Treating Pain in Diabetic Neuropathy: Current and Developmental Drugs

  2020cites this paper
• Duloxetine and Angiotensin II Receptor Blocker Combination Potentially Induce Severe Hyponatremia in an Elderly Woman

  2019cites this paper
• Adverse Effects of Pharmacological Treatments of Major Depression in Older Adults

  2019cites this paper
• Acceptability of escitalopram versus duloxetine in outpatients with depression who did not respond to initial second‐generation antidepressants: Study protocol for a randomized, parallel‐group, non‐inferiority trial

  2019cites this paper
• Efficacy and tolerability of duloxetine in patients with knee osteoarthritis: a meta‐analysis of randomised controlled trials

  2019cites this paper
• An Open-Label, 52-Week, Phase III Trial of Duloxetine in Japanese Patients with Chronic Low Back Pain.

  2019cites this paper
• Drug-induced liver injury

  2019cites this paper
• Neuropathies induites par chimiothérapie néo-adjuvante du cancer du sein : atteintes périphériques et centrales, mécanismes impliqués et perspectives thérapeutiques

  2018cites this paper
• Impact of duloxetine and dexamethasone for improving postoperative pain after laparoscopic gynecological surgeries: A randomized clinical trial

  2018cites this paper
• Ammoxetine attenuates diabetic neuropathic pain through inhibiting microglial activation and neuroinflammation in the spinal cord

  2018cites this paper
• Pain Management in Patients with Chronic Wounds

  2018cites this paper
• CHARACTERIZATION OF AGOMELATINE-INDUCED LIVER ENZYME INCREASE : FREQUENCY AND RISK FACTORS DERTERMINED FROM A POOLED ANALYSIS OF 7 , 605 TREATED PATIENTS

  2017cites this paper
• Prevalence and Treatment of Neuropathic Pain in Kidney and Liver Transplant Recipients.

  2017cites this paper
• A Guide to Medications Inducing Salivary Gland Dysfunction, Xerostomia, and Subjective Sialorrhea: A Systematic Review Sponsored by the World Workshop on Oral Medicine VI

  2016cites this paper
• Hip Osteoarthritis: Etiopathogenesis and Implications for Management

  2016cites this paper
• Comparison of duloxetine and methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder

  2016cites this paper
• Characterisation of Agomelatine-Induced Increase in Liver Enzymes: Frequency and Risk Factors Determined from a Pooled Analysis of 7605 Treated Patients

  2016cites this paper
• The Non-surgical Options for SUI—Is Any One Optimal?

  2016cites this paper
• Antidepressants and gabapentinoids in neuropathic pain: Mechanistic insights.

  2016cites this paper
• Managing Comorbidities in Patients with Chronic Heart Failure: First, Do No Harm

  2015cites this paper
• Smjernice za liječenje bolesnika s osteoartritisom kuka i/ili koljena

  2015cites this paper
• Preliminary Investigation on Duloxetine Efficacy in the Treatment of Children With Attention-Deficit Hyperactivity Disorder

  2015cites this paper
• From guideline to patient: a review of recent recommendations for pharmacotherapy of painful diabetic neuropathy.

  2015cites this paper
• Selective serotonin reuptake inhibitor drug interactions in patients receiving statins.

  2014cites this paper
• Pharmacokinetics of Antidepressants in Patients with Hepatic Impairment

  2014cites this paper
• Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia.

  2014cites this paper
• Risk of arrhythmia induced by psychotropic medications: a proposal for clinical management.

  2014cites this paper
• The efficacy of duloxetine, non-steroidal anti-inflammatory drugs, and opioids in osteoarthritis: a systematic literature review and meta-analysis

  2014cites this paper
• Effect of Perioperative Duloxetine on Postoperative pain relief following Anterior Cervical Microdiscectomy and fusion . A Pilot Study

  2014cites this paper
• A retrospective review of isolated duloxetine-exposure cases

  2013cites this paper
• Hepatotoxicity of Psychotropic Drugs and Drugs of Abuse

  2013cites this paper
• Safety and tolerability of duloxetine in elderly patients with major depressive disorder: a pooled analysis of two placebo-controlled studies

  2013influential citation
• Tolerability aspects in duloxetine-treated patients with depression: should one use a lower starting dose in clinical practice?

  2012influential citation
• Review of Efficacy and Safety of Duloxetine 40 to 60 mg Once Daily in Patients with Diabetic Peripheral Neuropathic Pain

  2012cites this paper
• Population Pharmacokinetics of Orally Administered Duloxetine in Patients

  2012cites this paper
• Apathy in currently nondepressed patients treated with a SSRI for a major depressive episode: outcomes following randomized switch to either duloxetine or escitalopram.

  2012cites this paper
• Neuropathic Pain: Mechanisms, Therapeutic Approach, and Interpretation of Clinical Trials

  2012cites this paper
• Chapter 25 – Drug-Induced Liver Injury

  2012cites this paper
• Prise en charge de la polyneuropathie diabétique douloureuse

  2011cites this paper
• Prise en charge de la polyneuropathie diabétique douloureuse: Référentiel de la Société francophone du diabète (SFD) 2010

  2011cites this paper
• Pharmacotherapy for Generalized Anxiety Disorder

  2011cites this paper
• Efficacy of Duloxetine in Patients with Chronic Pain Conditions

  2011cites this paper
• Duloxetine in the treatment of adolescents with attention deficit/hyperactivity disorder: an open‐label study

  2011cites this paper
• A Double‐blind, Randomized, Placebo‐controlled Study of the Efficacy and Safety of Duloxetine for the Treatment of Chronic Pain Due to Osteoarthritis of the Knee

  2011influential citation
• Adverse reactions to duloxetine in depression

  2011cites this paper
• Painful diabetic neuropathy: diagnosis and management.

  2011cites this paper
• Duloxetine

  2011cites this paper
• Epidemiologic Evaluation of Cardiovascular Risk in Patients Receiving Milnacipran, Venlafaxine, or Amitriptyline: Evidence from French Health Data

  2011cites this paper
• Duloxetine for the treatment of fibromyalgia

  2010cites this paper
• Efficacy and safety of duloxetine in fibromyalgia.

  2010cites this paper
• [New guidelines for the treatment of neuropathic pain].

  2010cites this paper
• Duloxetine 60 mg/day for the prevention of depressive recurrences: post hoc analyses from a recurrence prevention study

  2010cites this paper
• Nowe wytyczne dotyczące leczenia bólu neuropatycznego

  2010cites this paper
• Profile of Adverse Events with Duloxetine Treatment

  2010cites this paper
• Long-term safety of duloxetine during open-label compassionate use treatment of patients who completed previous duloxetine clinical trials

  2010cites this paper
• Duloxetine: Its Role in the Management of Chronic Pain

  2010cites this paper
• Chapter 26. Treatment of Neuropathic Pain

  2010cites this paper
• A European Multicenter Randomized Double-blind Placebo-controlled Monotherapy Clinical Trial of Milnacipran in Treatment of Fibromyalgia

  2010cites this paper
• EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision

  2010cites this paper
• Pain Response Profile of Patients With Fibromyalgia Treated With Duloxetine

  2010cites this paper
• Safety and tolerability of duloxetine in the acute management of diabetic peripheral neuropathic pain: analysis of pooled data from three placebo-controlled clinical trials

  2010cites this paper
• Chronic Pain after Injury Neuropathic Cancer Pain Dealing with Su ff ering Pharmacological Management of Neuropathic Pain Background

  2010cites this paper
• Duloxetine hepatotoxicity: a case‐series from the drug‐induced liver injury network

  2010cites this paper
• The pathophysiology, diagnosis and treatment of fibromyalgia.

  2010cites this paper
• Lymphocytic Colitis under Treatment with Duloxetine

  2010cites this paper
• The market lifecycle of duloxetine for urinary incontinence in Norway

  2010cites this paper
• Poster 52: Efficacy of Duloxetine in Patients With Chronic Pain Conditions

  2010cites this paper
• Duloxetin

  2010cites this paper
• Milnacipran for the management of fibromyalgia syndrome

  2010cites this paper
• EFNS guidelines on the pharmacological treatment of neuropathic pain: 2009 revision

  2010cites this paper
• Long-term safety, tolerability, and efficacy of duloxetine in the treatment of fibromyalgia.

  2010cites this paper
• Alpha2-adrenoceptor blockade potentiates the effect of duloxetine on sneeze induced urethral continence reflex in rats.

  2010cites this paper
• Safety and tolerability of duloxetine in the treatment of patients with fibromyalgia: pooled analysis of data from five clinical trials

  2009cites this paper
• NASHA/Dx Gel (ZuidexTM) for Stress Urinary Incontinence: Results from a Single-Centre Study of 150 Patients

  2009cites this paper
• Erratum to: Population pharmacokinetics of orally administered duloxetine in patients: implications for dosing recommendation

  2009cites this paper
• Duloxetine in the prevention of depressive recurrences: a randomized, double-blind, placebo-controlled trial.

  2009cites this paper
• Safety and tolerability of duloxetine treatment of diabetic peripheral neuropathic pain between patients with and without cardiovascular conditions.

  2009cites this paper
• Current Considerations in the Treatment of Generalized Anxiety Disorder

  2009cites this paper
• A Case Study of Salami Slicing: Pooled Analyses of Duloxetine for Depression

  2009cites this paper
• A double‐blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain

  2009cites this paper
• Psychosocial Issues in Fibromyalgia

  2009cites this paper
• Effects of Duloxetine on the Pharmacodynamics and Pharmacokinetics of Warfarin at Steady State in Healthy Subjects

  2009cites this paper
• Duloxetine

  2009cites this paper
• Duloxetine for treating painful neuropathy or chronic pain.

  2009cites this paper
• Pharmacotherapy of Fibromyalgia: Focus on Duloxetine

  2009cites this paper
• Duloxetine, a centrally acting analgesic, in the treatment of patients with osteoarthritis knee pain: A 13‐week, randomized, placebo‐controlled trial

  2009cites this paper
• Efficacy and safety of duloxetine for treatment of fibromyalgia in patients with or without major depressive disorder: Results from a 6‐month, randomized, double‐blind, placebo‐controlled, fixed‐dose trial☆

  2008cites this paper
• Medically serious adverse effects of newer antidepressants

  2008cites this paper
• Answers to the Most Common Questions About the Hepatic Safety Profile of Duloxetine

  2008cites this paper